Your browser doesn't support javascript.
loading
Short-Term Efficacy and Safety of Omidenepag Isopropyl in Patients with Normal-Tension Glaucoma.
Inoue, Kenji; Inoue, Junji; Kunimatsu-Sanuki, Shiho; Nozaki, Norie; Shimizu, Kosuke; Ishida, Kyoko; Tomita, Goji.
Afiliación
  • Inoue K; Inouye Eye Hospital, Chiyoda-Ku, Tokyo, Japan.
  • Inoue J; Nishikasai Inouye Eye Hospital, Edogawa-Ku, Tokyo, Japan.
  • Kunimatsu-Sanuki S; Nishikasai Inouye Eye Hospital, Edogawa-Ku, Tokyo, Japan.
  • Nozaki N; Omiya Inouye Eye Clinic, Saitama-Shi, Saitama, Japan.
  • Shimizu K; Sapporo Inouye Eye Clinic, Sapporo-Shi, Sapporo, Japan.
  • Ishida K; Department of Ophthalmology, Toho University Ohashi Medical Center, Meguro-ku, Tokyo, Japan.
  • Tomita G; Inouye Eye Hospital, Chiyoda-Ku, Tokyo, Japan.
Clin Ophthalmol ; 14: 2943-2949, 2020.
Article en En | MEDLINE | ID: mdl-33061280
PURPOSE: To retrospectively evaluate the short-term efficacy of omidenepag isopropyl (EYBELIS 0.002%) by assessing its intraocular pressure (IOP)-lowering capability and safety in patients with normal-tension glaucoma (NTG). PATIENTS AND METHODS: Fifty-four NTG patients (54 eyes) who were newly administrated with omidenepag isopropyl were enrolled in the study. The subjects comprised 22 men and 32 women, and the mean age of the subjects was 55.0 ± 14.1 years. The mean deviation value using the Humphrey visual field test program (30-2 SITA Standard) was -5.03 ± 3.38 dB. The following data were retrieved from the medical records and used for retrospective analyses: IOP at baseline 1-2 months and 3-4 months after administration. The frequency of non-responder patients who had less than 10% IOP reduction was evaluated. Patients were observed for adverse reactions and dropouts at each time point. RESULTS: IOP at baseline, after 1-2 months and after 3-4 months was 15.7 ± 2.6 mmHg, 13.5 ± 2.3 mmHg, and 13.6 ± 2.4 mmHg, respectively. There was a significant decrease in IOP after administration (p<0.0001). Eleven patients (22.4%) were non-responders. Adverse reactions occurred in 4 patients (7.4%), including conjunctival hyperemia in 3 patients (after 1 week, 2 weeks, and 1 month, respectively) and eye pain in 1 patient (after 1 month). Five patients (9.3%) dropped out of the study because of an adverse reaction in 3 patients, insufficient IOP reduction in 1 patient, and discontinuation of follow-up of 1 patient at our institution. CONCLUSION: After administration of omidenepag isopropyl, IOP in patients with NTG was significantly decreased. However, adverse reactions occurred in 7.4% of patients.
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Clin Ophthalmol Año: 2020 Tipo del documento: Article País de afiliación: Japón Pais de publicación: Nueva Zelanda
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Clin Ophthalmol Año: 2020 Tipo del documento: Article País de afiliación: Japón Pais de publicación: Nueva Zelanda